Abstract

 CADTH recommends that Imcivree be reimbursed by public drug plans for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS) if certain conditions are met.
 Imcivree should only be covered for patients who are aged 6 years and older and have a clinically or genetically confirmed diagnosis of BBS and obesity.
 Imcivree should only be reimbursed if prescribed by an endocrinologist, pediatric endocrinologist, and/or specialist in weight management or obesity and the cost of Imcivree is reduced. When first prescribed, Imcivree should only be reimbursed for 26 weeks. Reimbursement may be renewed on a yearly basis for patients who experience a clinically meaningful decrease in body weight or body mass index (BMI).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
